Funding provided to develop new therapy for acute liver failure

9 Sep 2015, 4:50 p.m.

Dr Kevin Mills

BRC-supported researcher Dr Kevin Mills has been awarded funding from the NIHR to investigate the regenerative ability of the liver following acute liver failure (ALF). If successful, the team hope that their research will lead to a novel therapy that could buy patients enough time to allow their livers to regenerate naturally, avoiding the need for liver transplantsThis research will be led by Professor Anil Dhawan at Kings College London in collaboration with Dr Mills at UCL Institute of Child Health. Specifically, the team aim to develop a novel technique where human liver cells grown in the lab are encapsulated in a material called alginate and delivered to a patient to help their ailing liver regenerate. Encasing the liver cells in alginate is particularly important as it reduces the need for immunosuppression.

Studies in the lab will focus on the feasibility of this novel therapy under lab conditions.

NIHR launches £13.7m investment into brain tumour research

The National Institute for Health and Care Research (NIHR) has announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.

New consortium aims to help improve care for arthritis patients

A new UK-led research group, including Great Ormond Street Hospital and University College London, aims to improve the lives of children, young people and adults with arthritis by defining for the first time what being in ‘remission’ from arthritis truly

Update for patients and families on industrial action - December 2025

As you may be aware, some of our Resident Doctors will be taking part in planned industrial action from 7am on Wednesday 17 December to 7am on Monday 22 December.

‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-Cell leukaemia

A groundbreaking new treatment using gene-edited immune cells, developed at GOSH and UCL has shown promising results in helping children and adults fight a rare and aggressive cancer